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Available online 8 June 2013A chemoenzymatic strategy for the synthesis of enantiomerically pure novel alkaloids (1S,3R)-
1-benzyl-2,3-dimethyl-1,2,3,4-tetrahydroisoquinolines is presented. The key steps are the biocatalytic
stereoselective reductive amination of substituted 1-phenylpropan-2-one derivatives to yield chiral
amines employing microbial x-transaminases, and the diastereoselective reduction of a Bischler–
Napieralski imine intermediate by catalytic hydrogenation in the presence of palladium on charcoal,
leading exclusively to the desired cis-isomer.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
Various 1-benzyl-1,2,3,4-tetrahydroisoquinolines1 act as anti-
spasmodic or hypotensive agents and some, such as norcoclaurine,
coclaurine, and N-methylcoclaurine, possess anti-HIV activity
in vitro.2 Consequently, benzylisoquinolines have been targets for
organic synthesis for a long time, and their asymmetric synthesis
has been achieved using many different strategies.3,4 Published
synthetic routes involve metal-catalyzed asymmetric hydrogena-
tions,5 intramolecular allylic aminations or amidations,6 photoin-
duced electrocyclic ring closure of aromatic enehydrazides,7
various metal- or organocatalyzed asymmetric alkylation reac-
tions,8 or chemical Pictet–Spengler reactions.9 Biocatalytic ap-
proaches10 include deracemization employing an amine
oxidase,11 kinetic resolution by the berberine bridge enzyme,12 or
the enzymatic Pictet–Spengler reaction.9,13 Since in nature the
(1S)-enantiomer is produced as a ﬁrst metabolite by the norcocla-
urine synthase,13 we set out to develop an alternative strategy to
access substituted (1S)-1-benzyl-1,2,3,4-tetrahydroisoquinolines
involving x-transaminases (x-TAs).142. Results and discussion
Our strategy was to control the stereochemistry at C1 of tetra-
hydroisoquinolines 5 by ﬁrst introducing a stereocenter at C3, thus
providing access to novel 1-benzyl-3-methyl-1,2,3,4-tetrahydro-
isoquinolines as ﬁnal products. For the synthesis of chiral amines
2/3, x-transaminases should be employed, while the ring closure
could be performed chemically.
First, control of the relative conﬁguration at position C1 in 5 by
the stereogenic amine center of 2 was investigated under various
reaction conditions (Scheme 1). For this purpose ketone 1was ami-
nated with methylamine to give racemic N-methyl amine 3, fol-
lowed by amide formation with a phenylacetic acid chloride
derivative. After the Bischler–Napieralski cyclization and further
reduction with sodium borohydride in methanol, a mixture of
the two diastereomers 5 was obtained in a trans:cis = 3:1 ratio. In
contrast, the catalytic hydrogenation of the intermediate iminium
ion of the Bischler–Napieralski reaction using palladium on char-
coal in methanol led exclusively to the formation of the cis-isomer
rac-cis-5. Additionally the protection groups were removed in the
same reaction step, making this approach favorable.
Since the cis-isomer 5 was obtained with perfect chemical ste-
reocontrol, and given that (1S)-benzylisoquinolines were desired,
the absolute conﬁguration at the C3 position of 5must be (R). Con-
sequently, three different (R)-stereoselective x-TAs were tested for
the asymmetric amination of 1 to prepare the corresponding (R)-
amine 2. The x-TAs employed originate from Aspergillus terreus,15
Hyphomona neptunium,15 and Arthrobacter sp.16 D-Alanine was used
as the amine donor for these enzymes, whereby the pyruvate
formed was removed either with a lactate dehydrogenase (LDH)
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Scheme 1. Inﬂuence of the chemical reduction method on the relative stereo-
chemistry of 5.
Table 1
Asymmetric reductive amination of 1a (50 mM) employing x-TAs from different
microorganisms. AlaDH or LDH was used to remove the coproduct pyruvate
x-TA Pyruvate removed by Conv. a (%) eeb (%)
A. terreus LDHc >99 >99 (R)
A. terreus AlaDH d >99 >99 (R)
Arthrobacter sp. LDHc >99 >99 (R)
Arthrobacter sp. AlaDH d >99 >99 (R)
H. neptunium LDHc 33 >99 (R)
H. neptunium AlaDH d 37 >99 (R)
ArRmut11-x-TAe n.a.f 89 >99 (R)
a The conversion after 24 h was determined by GC on an achiral phase and was
calculated from the areas of the substrate and product peaks.
b Determined by GC on a chiral phase of the samples derivatized as acetamides.
c Reaction conditions: substrate (50 mM), D-alanine (250 mM), phosphate buffer
(pH 7, 100 mM), PLP (1 mM), freeze-dried E. coli cells containing overexpressed x-
TA (20 mg), LDH (90 U), GDH (30 U), NAD+ (1 mM), glucose (150 mM).
d Reaction conditions: substrate (50 mM), D-alanine (250 mM), phosphate buffer
(pH 7, 100 mM), PLP (1 mM), freeze-dried E. coli cells containing overexpressed x-
TA (20 mg), AlaDH (12 U), FDH (11 U), NAD+ (1 mM), ammonium formate
(150 mM).
e Reaction conditions: substrate (50 mM), aqueous buffer (pH 11, 2-propylamine
1 M, PLP 0.5 mM), 20% v v1 DMSO, E. coli cells containing overexpressed x-TA
(20 mg).
f Not applicable. 2-Propylamine was used as the amine donor.
Table 2
Reductive amination of 1a (100 mM) after 24 h employing x-transaminases (x-TA)
from A. terreus and Arthrobacter sp. LDH and AlaDH were used to remove pyruvate
x-TA Pyruvate removed by Conv. (%)a
DMSO 15% v/v w/o DMSO
A. terreus LDH systemb 76 69
A. terreus AlaDHc 93 >99
Arthrobacter sp. LDH systemb 72 66
Arthrobacter sp. AlaDHc 75 71
a In all cases, the ee was >99% as determined for the amine derivatized to the
corresponding acetamides by GC on a chiral phase.
b Reaction conditions: substrate (100 mM), D-alanine (500 mM), phosphate buf-
fer (pH 7, 100 mM), PLP (1 mM), freeze-dried E. coli cells containing overexpressed
x-TA (20 mg), LDH (90 U), GDH (30 U), NAD+ (1 mM), glucose (300 mM).
c Reaction conditions: substrate (100 mM), D-alanine (500 mM), phosphate buf-
fer (pH 7, 100 mM), PLP (1 mM), freeze-dried E. coli cells containing overexpressed
x-TA (20 mg), AlaDH (12 U), FDH (11 U), NAD+ (1 mM), ammonium formate
(300 mM).
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the product side (Scheme 2).17 Furthermore, a variant of the Art-
hobacter sp. transaminase (ArRmut11-xTA)18 was tested using 2-
propylamine as the amine donor (Table 1). The best results were
obtained at a substrate concentration of 50 mM employing lyoph-
ilized Escherichia coli cells containing the overexpressed x-TAs
from A. terreus and Arthrobacter sp. No signiﬁcant difference was
observed when pyruvate was removed by LDH or AlaDH.
In order to improve the amination reaction, a twofold higher ke-
tone concentration (100 mM) was tested as well as the inﬂuence of
DMSO as a co-solvent (Table 2). The reaction was completed within
24 h only in the case of A. terreus transaminase in the absence of
DMSO and using the AlaDH system.
For the total synthesis of enantiomerically pure (1S,3R)-5a and
5b, the reductive amination of the corresponding ketones was per-
formed at 100 mM concentration and on a 50 mL scale (819/O
ω-transaminase
MeO MeO
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Scheme 2. Biocatalytic amination of ketone 1 followed b917 mg of ketones 1a–b, respectively). A. terreus x-TA and the
AlaDH system were used for the asymmetric amination of 1a–b
leading to enantiomerically pure (R)-2a–b (ee >99%) in 92% and
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and 209 mg of (1S,3R)-5a and 5b were obtained, corresponding
to an overall yield of 30% and 14%, respectively, over 6 steps.3. Conclusion
By employing a Bischler–Napieralski cyclization followed by a
reduction with Pd/C and hydrogen, the stereogenic center at C1
of benzylisoquinolines can be controlled using a chiral amine as
the substrate. Thus, cis-1-benzyl-2,3-dimethylisoquinolines can
be obtained in excellent enantiomeric and diastereomeric purity,
making this method an effective procedure for the asymmetric
synthesis of unnatural tetrahydroisoquinoline alkaloids bearing
two stereogenic centers. The asymmetric key steps are the biocata-
lytic stereoselective amination of the prochiral ketones on one
hand, as well as stereocontrolled reduction of the intermediate Bis-
chler–Napieralski imines on the other hand.
4. Experimental
4.1. General
Nuclear magnetic resonance (NMR) spectra were recorded on a
Bruker Avance 300 at operating frequencies of 300 MHz (1H NMR)
or 75 MHz (13C NMR). Chemical shifts are given in parts per million
(ppm) relative to TMS (d = 0 ppm) and coupling constants (J) are re-
ported in Hertz (Hz). Optical rotation values ½a20D were measured at
589 nm (Na line) on a Perkin–Elmer Polarimeter 341 using a cuv-
ette of 1 dm path length. Melting points were determined on a Gal-
lenkamp MPD350 apparatus and are uncorrected. Thin layer
chromatography was carried out on silica gel 60 F254 plates and
compounds were visualized either by spraying with Mo reagent
[(NH4)6Mo7O244H2O (100 g L1), Ce(SO4)24H2O (4 g L1) in
H2SO4 (10%)] or by UV. Unit resolution GC–MS analyses were per-
formed using electron impact (EI) ionization at 70 eV and quadru-
pole mass selection. High resolution MS analyses were performed
using electron impact (EI) ionization at 70 eV and time-of-ﬂight
(TOF) mass selection. Unless otherwise noted, reagents and organic
solvents were obtained from commercially available sources and
were used without further puriﬁcation. HPLC analysis was per-
formed on a Shimadzu system (Communication Bus Module
CBM-20 A, Column Oven CTO-20 AC, Degasser DGU-20 A5, Liquid
Chromatograph LC-20 AD, Auto sampler SIL-20 AC, Diode Array
Detector SPD-M20 A) using an achiral C18 column (Phenomenex,
LUNA C18, 0.46 cm  25 cm, 5 mm). Eluent: buffer (30 mM
HCO2NH4, pH 2.8)/methanol/acetonitrile = 67/18/15 (isocratic);
ﬂow rate: 0.5 mL/min; column temperature: 20 C; detection
wavelength: 280 nm. HPLC of enantiomers was performed on a
chiral stationary phase (Chiralcel OJ). Eluent: n-heptane/2-propa-
nol = 90/10 + 0.1% formic acid (isocratic); ﬂow rate: 0.75 mL/min.
GC analytics were performed using an Agilent 7890 A GC sys-
tem, equipped with an FID detector and using an Agilent J&W
DB-1701 column (30 m, 250 lm, 0.25 lm). Carrier: Helium at con-
stant pressure: 1 bar. T injector: 250 C. Program: 80 C, hold
6.5 min. Gradient 10 C/min up to 160 C, hold 5 min. Gradient
20 C/min up to 200 C, hold 2 min. Retention times: 1a:
20.3 min, 2a: 19.3 min. 1b: 22.4 min, 2b: 21.6 min.
For the determination of the ee the column Varian Chrompack
Chirasel Dex-CB (25 m, 320 lm, 0.25 lm) was employed. Carrier:
Hydrogen at constant ﬂow: 1.7 mL/min. T injector: 200 C. Pro-
gram: 100 C, hold 2 min. Gradient 1 C/min up to 130 C, hold
5 min. Gradient: 10 C/min up to 180 C, hold 20 min. Retention
times: (S)-2a: 44 min, (R)-2a: 44.3 min, (R)-2b: 47.6 min.
Enantiomeric purity of 5b: HPLC, Chiralcel OJ (Daicel Chemical
Industries, 0.46 cm  25 cm, Lot. No.: OJ00CE-NK006). Eluent: n-heptane (0.1% formic acid) and 2-propanol (0.1% formic acid)
(70:30), ﬂow rate 0.5 mL min1 (isocratic), detection wavelength:
280 nm. Retention times: (1S,3R): 11.2 min, (1R,3S): 12.5 min.
Lyophilized E. coli cells containing overexpressed (R)-selective
x-TAs and AlaDH were prepared as previously described.17 L-Lac-
tate dehydrogenase from rabbit muscle (lyophilized powder,
136 U mg1 protein, one unit will reduce 1.0 lmol of pyruvate to
L-lactate per min at pH 7 at 25 C, catalog no. 61309) was pur-
chased from Sigma–Aldrich (Vienna, Austria). Glucose dehydroge-
nase (lyophilized powder, 25 U mg1, one unit will oxidize 1 lmol
b-D-glucose to D-glucono-d-lactone per min at pH 8.0 and 37 C,
catalog no. B-4) was purchased from X-zyme (Düsseldorf, Ger-
many). Formate dehydrogenase from Candida boidinii (lyophilized
crude enzyme, 2.2 U mg1, one unit will oxidize 1.0 lmole of for-
mate to CO2 per min at pH 7.6 at 37 C, catalog no. FDH-101) and
b-NAD free acid was purchased from Codexis (Redwood City, CA,
USA).
4.2. Biocatalytic procedures
The biocatalytic reactions using x-TAs were performed at 30 C
in a sodium phosphate buffer (100 mM, pH 7) containing pyridoxal
50-phosphate (PLP, 1 mM) and NAD+ (free acid, 1 mM). DMSO was
added in the indicated experiments (15%, v v1). Biotransforma-
tions with ArRmut11-xTA were performed at 45 C in an aqueous
solution of 2-propylamine (1 M), at pH 11 (adjusted with aqueous
6 M HCl) in the presence of DMSO (20%, v v1) as cosolvent and
pyridoxal 50-phosphate (0.5 mM). Eppendorf tubes were shaken
on orbital shakers in a horizontal position to ensure improved
mixing.
4.2.1. Representative example for the reductive amination
employing the AlaDH system
Lyophilized cells of E. coli BL21 (DE3) containing overexpressed
x-TA (20 mg) were rehydrated in an Eppendorf tube (2 mL) in a
phosphate buffer (1 mL, 100 mM, pH 7, 1 mM PLP, 1 mM NAD+)
for 30 min at 30 C and 120 rpm on an orbital shaker. Ammonium
formate (150 mM), D-alanine (250 mM, 22.3 mg), L-alanine dehy-
drogenase (12 U), or disrupted cells of E. coli BL21 (DE3) containing
overexpressed AlaDH (20 mg), formate dehydrogenase (11 U), and
ketone 1a (50 mM) were added. In the experiments with 100 mM
substrate concentration, the amounts of D-alanine and the ammo-
nium formate were doubled (500 mM and 300 mM, respectively).
DMSO was also added in selected experiments (15%, v v1). The
mixture was shaken at 30 C and 120 rpm. The reaction was
quenched after 24 h by the addition of aqueous 10 M NaOH
(200 lL) and the reaction mixture was extracted with ethyl acetate
(2  500 lL). The combined organic phases were dried (Na2SO4)
and the conversion was measured by GC.
4.2.2. Representative example for the amination employing the
LDH system
Lyophilized cells of E. coli BL21 (DE3) containing overexpressed
x-TA (20 mg) were rehydrated in an Eppendorf tube (2 mL) in
phosphate buffer (1 mL, 100 mM, pH 7, 1 mM PLP, 1 mM NAD+)
for 30 min at 30 C and 120 rpm on an orbital shaker. Glucose
(150 mM), D-alanine (250 mM, 22.3 mg), lactate dehydrogenase
(90 U), glucose dehydrogenase (30 U), and ketone 1a (50 mM) were
added. DMSO was also added in selected experiments (15% v v1).
The mixture was shaken at 30 C and 120 rpm. The reaction was
quenched and worked up as described above.
4.2.3. Representative example for amination employing the 2-
propylamine system
Lyophilized cells of E. coli BL21 (DE3)/pET21a-ArRmut11-x-TA
(20 mg) were rehydrated in a glass vial (4 mL) in an aqueous buffer
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for 30 min at 30 C and 120 rpm on an orbital shaker. Then, DMSO
(200 lL) and ketone 1a (50 mM) were added. The vial was closed
with an airtight cap and shaken at 45 C and 120 rpm in an upright
position. The reaction was quenched and worked up as described
above.
4.2.4. Up-scaling of the amination of ketones 1a and 1b
Lyophilized cells of E. coli BL21 (DE3) containing overexpressed
AlaDH from Bacillus subtilis (0.5 g) were suspended in a phosphate
buffer (50 mL, 100 mM, pH 7) and subjected to ultrasonication
with a Branson Digital Soniﬁer (8 min, 40% Amplitude, 1 s Pulse,
4 s Pause). The disrupted cells were centrifuged (16,000 rpm,
15 min, 4 C) and the supernatant separated and divided into two
aliquots in conical bottom centrifuge tubes with screw caps
(25 mL/tube). Lyophilized cells of E. coli BL21 (DE3) containing
overexpressed x-transaminase from A. terreus were added to each
tube (0.5 g) and rehydrated for 30 min at 30 C and 120 rpm on an
orbital shaker. Then, PLP (1 mM, 6.63 mg), NAD+ (1 mM, 17 mg),
ammonium formate (300 mM, 480 mg), D-alanine (500 mM,
1115 mg), formate dehydrogenase (11 U, 125 mg) and ketones 1a
or 1b (100 mM) were added. The mixture was shaken at 30 C
and 120 rpm. The reaction was quenched after 24 h by the addition
of aqueous 10 M NaOH (pH 10) and the reaction mixture was ex-
tracted with EtOAc (3  30 mL). The combined organic phases
were dried (Na2SO4) and conversions were determined by GC as
described above.
1-(3-Methoxyphenyl)propan-2-amine (R)-2a
Obtained as a pale yellow liquid. Yield: 763 mg (92%). ee: >99%.
½a20D ¼ 33:4 (c 1.13, CHCl3). Lit.19 for (S)-2a ½a20D ¼ 33:5 (c 1.00
CHCl3) ee: 96%. 1H NMR (CDCl3, 300 MHz): d = 1.14 (3H, d,
J = 6.3 Hz, CH3), 1.49 (2H, br s, NH2), 2.50 (1H, dd, J = 8.1, 13.3 Hz,
CH2CH), 2.71 (1H, dd, J = 5.4, 13.3 Hz, CH2CH), 3.22–3.15 (1H, m,
CH2CH), 3.81 (3H, s, OCH3), 6.80–6.75 (3H, m, Ar), 7.23 (1H, t,
J = 7.6 Hz, Ar). 13C NMR (CDCl3, 75 MHz): d = 23.6, 46.7, 48.4,
55.1, 111.5, 115.0, 121.6, 129.4, 141.3, 159.6. HRMS calculated
for C10H15NO [M+]: 165.1154; found: 165.1159.
1-(3,4-Dimethoxyphenyl)propan-2-amine (R)-2b
Obtained as a viscous liquid which formed white crystals after
prolonged standing. Yield: 711 mg (77%). Mp: 104–105 C. ee:
>99%. ½a20D ¼ 31:9 (c 1.00, CHCl3). Lit.20 for (R)-2b ½a20D ¼ 30:9
(c 4.13, CHCl3). 1H NMR (CDCl3, 300 MHz): d = 1.12 (3H, d,
J = 6.3 Hz, CH3), 1.49 (2H, br s, NH2), 2.44 (1H, dd, J = 8.1, 13.4 Hz,
CH2CH), 2.67 (1H, dd, J = 5.1, 13.4 Hz, CH2CH), 3.18–3.11 (1H, m,
CH2CH), 3.86 (3H, s, OCH3), 3.87 (3H, s, OCH3), 6.74–6.71 (2H, m,
Ar), 6.81 (1H, d, J = 8.1 Hz, Ar). 13C NMR (CDCl3, 75 MHz):
d = 23.5, 46.1, 48.5, 55.8, 55.9, 111.2, 112.3, 121.1, 132.3, 147.4,
148.8. HRMS calculated for C11H17NO2 [M+]: 195.1259; found:
195.1266.
4.3. Determination of the enantiomeric purity
The enantiomeric excess (ee) of amines 2a and 2b was analyzed
by GC on a chiral phase after derivatization to the corresponding
acetamides. Derivatization was performed by adding 4-(N,N-
dimethylamino)pyridine (DMAP, 5 mg) dissolved in acetic anhy-
dride (100 mL). After washing with water and drying (Na2SO4),
the ee value of the derivatized compound was measured by GC.
4.4. General procedure for the preparation of rac-3a–b
The carbonyl compounds 1a–b (10 mmol), titanium(IV) iso-
propoxide (5.9 mL, 20 mmol), methylamine hydrochloride (1.35 g,
20 mmol), and triethylamine (2.79 mL, 20 mmol) in absolute EtOH(15 mL) were stirred under an argon atmosphere at ambient tem-
perature for 16 h. Sodium borohydride (0.57 g, 15 mmol) was then
added and the resulting mixture was stirred for an additional 6 h at
ambient temperature. The reaction was then quenched by pouring
into NH4OH (2 M, 30 mL). The resulting inorganic precipitate was
ﬁltered off and washed with CH2Cl2 (50 mL). The organic layer
was separated and the remaining aqueous layer was extracted
once with CH2Cl2 (50 mL). The combined organic layers were then
extracted once with HCl (1 M, 25 mL) to separate the neutral mate-
rials. The acidic aqueous layer was washed once with CH2Cl2
(50 mL), then basiﬁed with aqueous NaOH (2 M) to pH 10–12
and extracted with CH2Cl2 (50 mL  3). The combined organic ex-
tracts were washed with brine (50 mL), dried (Na2SO4), and con-
centrated in vacuo to afford the N-methyl secondary amines.
1-(3-Methoxyphenyl)-N-methylpropane-2-amine rac-3a
Obtained as a yellow oil. Isolated yield 1.29 g (72%). 1H NMR
(CDCl3, 300 MHz) d = 1.08 (3H, d, J = 6.3 Hz, CH3), 2.05 (1H, br s,
NH), 2.41 (3H, s, NCH3), 2.85–2.58 (3H, m overlap, CH2-CH), 3.81
(3H, s, OCH3), 6.80–6.75 (3H, m, Ar), 7.22 (1H, t, J = 7.7 Hz, Ar).
13C NMR (CDCl3, 75 MHz): d = 19.8, 34.0, 43.6, 55.0, 56.2, 111.4,
115.0, 121.7, 129.3, 141.1, 159.6. HRMS calculated for C11H17NO
[M+H]: 178.1232; found: 178.1225.
1-(3,4-Dimethoxyphenyl)-N-methylpropan-2-amine rac-3b
Obtained as a viscous yellow oil. Isolated yield 1.34 g (64%). 1H
NMR (CDCl3, 300 Mhz) d = 1.04 (3H, d, J = 6.0 Hz, CH3), 1.49 (1H, br
s, NH), 2.37 (3H, s, NCH3), 2.58 (2H, d, J = 5.8 Hz, CH2-CH), 2.73 (1H,
m, CH2-CH), 3.85 (3H, s, OCH3), 3.86 (3H, s, OCH3), 6.80–6.70 (3H,
m, Ar). 13C NMR (CDCl3, 75 MHz): d = 19.8, 34.2, 43.3, 55.9, 56.5,
111.3, 112.5, 121.3, 132.1, 147.5, 148.9. HRMS calculated for
C12H19NO2: [M+H]: 208.1338; found: 208.1348.
4.5. General procedure for the preparation of rac-4a–b
Amines 3a–b (10 mmol of 3a or 6.4 mmol of 3b) were dissolved
in CHCl3 (30 mL). Next, 3% aqueous NaOH solution (150 mL) was
added and the mixture was cooled to 0 C using an ice bath. A solu-
tion of 3-benzyloxyphenylacetyl chloride (2.88 g, 11.0 mmol) in
chloroform (20 mL) was added dropwise over 1 h to the vigorously
stirred mixture. The ice bath was removed and stirring was contin-
ued for 2 h at room temperature. The phases were separated and
the aqueous layer was extracted with CHCl3 (50 mL). The com-
bined organic phases were washed with dilute HCl solution
(0.1 N, 100 mL), then brine (100 mL), and dried over Na2SO4. Evap-
oration of the solvent under reduced pressure yielded a highly vis-
cous yellow liquid. Flash chromatography (silica; petrol ether/
EtOAc = 6.6/3.5) afforded the corresponding methylacetamides.2-(3-(Benzyloxy)phenyl)-N-(1-(3-methoxyphenyl)propan-2-yl)-
N-methylacetamide rac-4a
Obtained as a pale yellowish liquid (2.99 g, 74%). The NMR spec-
tra revealed the presence of a mixture of the cis- and trans-isomers.
1H NMR (CDCl3, 300 MHz): d = 0.95 (3H, d, J = 6.6 Hz, CH-CH3), 1.02
(3H, d, J = 6.9 Hz, CH-CH3), 2.53–2.61 (2H, m, Ph-CH2-CH), 2.63–
2.66 (2H, m, Ph-CH2-CH), 2.68 (3H, s, N-CH3), 2.79 (3H, s, N-CH3),
3.32 (2H, s, Ph-CH2-CO), 3.52 (2H, s, Ph-CH2-CO), 3.67 (6H, s,
OCH3), 3.94–3.99 (1H, m, CH), 4.92 (2H, s, Ph-CH2-O), 4.95 (2H, s,
Ph-CH2-O), 4.99–5.03 (1H, m, CH), 6.46–6.77 (12H, m, Ar), 7.05–
7.36 (14H, m, Ar). 13C NMR (CDCl3, 75 MHz): d = 17.2, 18.4, 26.6,
29.5, 40.1, 40.7, 41.2, 41.8, 49.4, 53.4, 54.7, 55.2, 69.4, 69.9,
111.8, 112.0, 113.1, 113.3, 114.3, 114.8, 115.0, 115.1, 121.2,
121.3, 127.4, 127.5, 127.9, 128.5, 129.3, 129.6, 136.6, 136.9,
137.1, 139.9, 140.0, 159.0, 159.6, 159.8, 170.6, 170.7. HRMS calcu-
lated for C26H29NO3 [M+]: 403.2148; found: 403.2151.
748 A. A. Orden et al. / Tetrahedron: Asymmetry 24 (2013) 744–7492-(3-(Benzyloxy)phenyl)-N-(1-(3,4-dimethoxyphenyl)propan-2-
yl)-N-methylacetamide rac-4b
Obtained as a brownish liquid (1.60 g, 58%). The NMR spectra
revealed the presence of a mixture of the cis- and trans-isomers.
1H NMR (CDCl3, 300 MHz): d = 1.05 (3H, d, J = 6.5 Hz, CH-CH3),
1.11 (3H, d, J = 6.7 Hz, CH-CH3), 2.56–2.62 (2H, m, Ph-CH2-CH),
2.68–2.70 (2H, m, Ph-CH2-CH), 2.75 (3H, s, N-CH3), 2.89 (3H, s, N-
CH3), 3.39 (2H, s, Ph-CH2-CO), 3.60 (2H, s, Ph-CH2-CO), 3.83 (6H,
s, OCH3), 3.84 (6H, s, OCH3), 4.03–4.00 (1H, m, CH), 5.04 (2H, s,
Ph-CH2-O), 5.08 (2H, s, Ph-CH2-O), 5.11–5.08 (1H, m, CH), 6.86–
6.49 (12H, m, Ar), 7.44–7.14 (12H, m, Ar). 13C NMR (CDCl3,
75 MHz): d = 17.2, 18.4, 26.7, 29.5, 39.7, 40.3, 41.3, 41.9, 49.3,
55.0, 55.8, 55.9, 56.0, 69.8, 69.9, 111.0, 111.4, 112.0, 112.1, 113.1,
115.0, 115.2, 120.9, 121.0, 121.1, 121.2, 127.5, 127.6, 128.0,
128.6, 129.7, 130.9, 131.0, 136.6, 137.0, 137.1, 147.5, 147.8,
148.8, 149.0, 159.0, 159.1, 170.7, 170.8. HRMS calculated for
C27H31NO4 [M+]: 433.2253; found: 433.2254.
4.6. General procedure for the preparation of rac-5a–b
To a solution of 4a–b (7.18 mmol of 4a or 4.32 mmol of 4b) in
dry acetonitrile (70 mL), POCl3 (3.23 g, 21.1 mmol) was added
and the mixture was reﬂuxed for 3 h under an argon atmosphere.
The solvent and excess POCl3 were evaporated under reduced pres-
sure and the residue was dissolved in dry methanol, put under ar-
gon and cooled to 0 C using an ice bath. Next, NaBH4 (1.98 g,
52.2 mmol) was added in portions to the stirred mixture. The ice
bath was then removed and stirring was continued for 14 h at
room temperature. The solvent was evaporated and the residue
was treated with a half-saturated Na2CO3 solution (100 mL). The
product was extracted with CH2Cl2 (3  50 mL), the combined or-
ganic phases were dried over Na2SO4 and evaporated under re-
duced pressure to give a pale yellowish liquid. Analysis by TLC
showed two products, which were separated by ﬂash chromatog-
raphy (silica; EtOAc/MeOH = 95/5). Each product was treated with
Pd (10% on activated charcoal; 200 mg), acetic acid (470 mg,
7.8 mmol), and dry methanol (20 mL) and stirred under an H2
atmosphere (balloon) for 16 h. The mixture was ﬁltered through
Celite, washed with methanol (50 mL), and evaporated under re-
duced pressure. The residue was dissolved in CH2Cl2 and washed
with a half-saturated NaHCO3 solution (40 mL). The organic phase
was dried over Na2SO4 and evaporated under reduced pressure.
The residue was puriﬁed by silica gel ﬂash chromatography
(EtOAc/MeOH = 95/5).
cis-1-(3-Hydroxybenzyl)-6-methoxy-2,3-dimethyl-1,2,3,4-
tetrahydroisoquinoline cis-5a
Obtained as white crystals, which were not soluble in CH2Cl2 or
CHCl3. Yield 298 mg (14%). Mp: 125–126 C. 1H NMR (MeOD,
300 MHz): d = 1.24 (3H, d, J = 5.7 Hz, CH3-CH), 2.41 (3H, s, NCH3),
2.52–2.58 (3H, m overlap, Ph-CH2-CH-CH3), 2.83 (1H, dd, J = 7.5,
13.8 Hz, Ph-CH2-CH), 3.06 (1H, dd, J = 4.5, 13.8 Hz, Ph-CH2-CH),
3.73 (3H, s, OCH3), 3.83 (1H, dd, J = 4.5, 7.5 Hz, Ph-CH2-CH), 6.57–
6.62 (5H, m, Ar), 6.71–6.75 (1H, m, Ar), 7.01–7.06 (1H, m, Ar). 13C
NMR (MeOD, 75 MHz): d = 20.0, 36.5, 38.6, 43.7, 54.1, 55.7, 66.7,
111.3, 111.9, 112.5, 116.2, 120.6, 127.8, 128.5, 129.5, 136.7,
141.2, 156.7, 158.0. HRMS calculated for C19H23NO2 [M+H]:
296.1650; found: 296.1664. Retention time on HPLC (achiral C18
column, details see above): 26.2 min.
trans-1-(3-Hydroxybenzyl)-6-methoxy-2,3-dimethyl-1,2,3,4-
tetrahydroisoquinoline trans-5a
Obtained as a yellow solid foam. Yield 946 mg (44%). Mp: 46–
49 C. 1H NMR (CDCl3, 300 MHz): d = 1.28 (3H, d, J = 6.6 Hz, CH3-
CH), 2.39 (3H, s, NCH3), 2.66–2.70 (2H, m, Ph-CH2-CH), 2.82 (1H,
dd, J = 8.4, 13.2 Hz Ph-CH2-CH), 3.25 (1H, dd, J = 4.8, 13.2 Hz Ph-CH2-CH), 3.46–3.54 (1H, m, CH-CH3), 3.76 (3H, s, OCH3), 3.94 (1H,
dd, J = 4.8, 8.4 Hz, Ph-CH2-CH), 6.46–6.62 (4H, m, Ar), 4.70–6.72
(2H, m, Ar), 7.07–7.13 (1H, m, Ar). 13C NMR (CDCl3, 75 MHz):
d = 18.7, 31.8, 35.7, 42.2, 47.3, 55.1, 55.2, 66.0, 111.6, 113.2,
113.8, 116.3, 121.8, 128.4, 129.2, 129.3, 134.8, 141.2, 156.6,
157.9. HRMS calculated for C19H23NO2 [M+H]: 296.1650; found:
296.1646. Retention time on HPLC (achiral C18 column, details
see above): 25.9 min.
cis-1-(3-Hydroxybenzyl)-6,7-dimethoxy-2,3-dimethyl-1,2,3,4-
tetrahydroisoquinoline cis-5b
Obtained as white crystals, which were not soluble in CH2Cl2 or
CHCl3. Yield 246 mg (17%). Mp: 159–161 C. 1H NMR (CDCl3,
300 MHz, analyzed as a benzyloxy derivative) d = 1.22 (3H, d,
J = 5.7 Hz, CH3-CH), 2.46 (3H, s, NCH3), 2.55–2.48 (3H, m overlap
Ph-CH2-CH-CH3), 2.89–2.75 (1H, m, Ph-CH2-CH), 3.14 (1H, dd,
J = 3.3, 14.5 Hz, Ph-CH2-CH), 3.58 (3H, s, OCH3), 3.78–3.75 (1H, m,
Ph-CH2-CH), 3.83 (3H, s, OCH3) 4.99 (2H, s, Ph-CH2-O), 6.20 (1H,
s, Ar), 6.53 (1H, s, Ar), 6.82–6.69 (3H, m, Ar). 7.14 (1H, t,
J = 7.8 Hz, Ar), 7.44–7.30 (5H, m, Ar). 13C NMR (CHCl3, 75 MHz):
d = 21.7, 37.1, 40.4, 44.9, 55.4, 55.8, 67.1, 70.0, 76.7, 77.1, 77.6,
110.4, 112.4, 116.6, 122.9, 127.5, 127.9, 128.1, 128.6, 128.9,
129.6, 137.2, 141.6, 146.6, 147.0, 158.5. HRMS calculated for
C20H25NO3 [M+H]: 326.1756; found: 326.1735.
trans-1-(3-Hydroxybenzyl)-6,7-dimethoxy-2,3-dimethyl-
1,2,3,4-tetrahydroisoquinoline trans-5b
Obtained as yellow crystals. Yield 703 mg (49%). Mp: 82–84 C.
1H NMR (CDCl3, 300 MHz) d = 1.76 (3H, d, J = 6.0 Hz, CH3-CH), 2.99
(3H, s, NCH3), 3.16–3.07 (2H, m, Ph-CH2-CH-CH3), 3.34–3.22 (1H,
m, Ph-CH2-CH), 3.77–3.69 (1H, m, Ph-CH2-CH), 3.83 (3H, s, OCH3)
4.52–4.36 (4H, overlap s + m, OCH3, Ph-CH2-CH-CH3), 4.57–4.54
(1H, m, Ph-CH2-CH), 6.25 (1H, s, Ar), 6.95 (1H, s, Ar), 7.13–7.03
(3H, m, Ar), 7.58–7.53 (1H, m, Ar). 13C NMR (CHCl3, 75 MHz):
d = 19.2, 31.5, 36.1, 42.1, 47.3, 55.4, 55.8, 66.6, 111.1, 112.4,
116.5, 122.7, 125.8, 142.0, 146.3, 147.3, 158.7. HRMS calculated
for C20H25NO3 [M+H]: 326.1756; found: 326.1724.
4.7. General procedure for the preparation of rac-cis-5a–b
To a solution of 4a–b (50 mg, 0.12 mmol) in dry acetonitrile
(3 mL), POCl3 (56 mg, 0.36 mmol) was added and the mixture
was reﬂuxed for 3 h under an argon atmosphere. The solvent and
excess POCl3 were evaporated under reduced pressure and the res-
idue was dissolved in dry methanol (3 mL). Next, Pd (10% on acti-
vated charcoal; 30 mg) was added and the mixture was stirred
under an H2 atmosphere (balloon) for 5 h. The solids were removed
by ﬁltration through Celite, washed with MeOH (10 mL), and the
solvent was evaporated under reduced pressure. The residue was
dissolved in CH2Cl2 and washed with a half-saturated NaHCO3
solution (15 mL). The organic phase was dried over Na2SO4 and
evaporated under reduced pressure. The products of the reaction
were analyzed by GC–MS and TLC (EtOAc/MeOH = 95/5) and their
Rf and tr compared to cis-5a and cis-5b obtained as described
above.
4.8. Preparation of (R)-3a–b
To a solution of (R)-2a (760 mg, 4.6 mmol) in CH2Cl2 (20 mL)
were added triethylamine (512 mg, 5.06 mmol) and ethyl chloro-
formate (599 mg, 5.52 mmol) and the mixture was stirred for 3 h
at room temperature. Water (25 mL) was added, the phases were
separated, and the aqueous phase was extracted with CH2Cl2
(2  15 mL). The combined organic phases were dried over Na2SO4
and evaporated under reduced pressure to give the corresponding
carbamates.
A. A. Orden et al. / Tetrahedron: Asymmetry 24 (2013) 744–749 749(R)-Ethyl 1-(3-methoxyphenyl)propan-2-ylcarbamate
Compound was obtained in 1007 mg (92%) as a yellow liquid.
½a20D ¼ þ9:2 (c 0.83, CHCl3).
(R)-Ethyl 1-(3,4-dimethoxyphenyl)propan-2-ylcarbamate
Compound was obtained in 773 mg (86%) as a white solid (mp:
81–83 C). ½a20D ¼ þ7:2 (c 1.00, CHCl3).
A solution of the corresponding carbamates (2.5 mmol) in anhy-
drous THF (15 mL) under argon atmosphere was cooled to 0 C
using an ice bath. LiAlH4 (805 mg, 21 mmol) was added in portions
to the stirred solution; afterward the ice bath was removed and the
mixture was reﬂuxed for 6 h. The suspension was diluted with THF
(15 mL) and cooled to 0 C on an ice bath. To the vigorously stirred
mixture were added: water (805 lL), 15% NaOH solution (805 lL),
and again water (2.415 mL). Then, the ice bath was removed and
stirring continued for 1 h at room temperature. The resulting sus-
pension was ﬁltered through Celite, washed with THF, dried over
Na2SO4, and evaporated under reduced pressure. Puriﬁcation was
performed by ﬂash chromatography (silica; CH2Cl2/MeOH/
NH4OH = 90/9/1).
(R)-1-(3-methoxyphenyl)-N-methylpropan-2-amine (R)-3a
Compound was obtained in 534 mg (70%) as a yellow liquid.
½a20D ¼ 4:2 (c 2.35, CH2Cl2). Lit.21 for (S)-3a ½a20D ¼ þ5:8 (c 1.98,
CH2Cl2).
(R)-1-(3,4-dimethoxyphenyl)-N-methylpropan-2-amine (R)-3b
Compound was obtained in 297 mg (57%) as a yellow liquid.
(1S,3R)-5a
This compound was prepared following the procedure as de-
scribed for rac-5a–b. Yield: 450 mg (30% over 6 steps from 1a).
½a20D ¼ 3:6 (c 1.79, MeOH).
(1S,3R)-5b
This compound was prepared following the procedure as de-
scribed for rac-5a–b. Yield: 209 mg (14% over 6 steps from 1b).
½a20D ¼ 4:3 (c 0.18, MeOH).
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